Edition:
India

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

324.46USD
14 Dec 2017
Change (% chg)

$-6.25 (-1.89%)
Prev Close
$330.71
Open
$332.00
Day's High
$332.00
Day's Low
$323.85
Volume
508,490
Avg. Vol
1,256,239
52-wk High
$348.84
52-wk Low
$244.28

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Biogen Appoints Mark Hernon As SVP, Chief Information Officer

* BIOGEN APPOINTS MARK HERNON AS SVP, CHIEF INFORMATION OFFICER Source text for Eikon: Further company coverage:

04 Dec 2017

BRIEF-Sarissa Capital Management's Alexander​ ‍Denner Buys 30,000 Shares Of Biogen's Common Stock

* SARISSA CAPITAL MANAGEMENT'S ALEXANDER​ ‍DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING Source text: (http://bit.ly/2niyLpi) Further company coverage:

30 Nov 2017

Biogen boosts multiple sclerosis holding with Alkermes license

Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

27 Nov 2017

Biogen boosts multiple sclerosis holding with Alkermes license

Nov 27 Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

27 Nov 2017

BRIEF-Biogen appoints Jeff Capello as executive vice president and chief financial officer

* Appoints Jeff Capello as executive vice president and chief financial officer

21 Nov 2017

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

17 Nov 2017

Bill Gates makes $100 million personal investment to fight Alzheimer's

LONDON, Nov 13 Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.

13 Nov 2017

BRIEF-Biogen presents new data from long-term extension of phase 1B study

* Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab

02 Nov 2017

UPDATE 1-Sobi to scale up in North America as Q3 beats expectations

Oct 25 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Wednesday a bigger jump than expected in quarterly core profit, raised its profit and sales guidance, and said it planned to boost operations in North America.

25 Oct 2017

US STOCKS-Dow jumps with upbeat 3M, Caterpillar earnings

* Indexes up: Dow 0.7 pct, S&P 500 0.2 pct, Nasdaq 0.2 pct (Adds background in paragraph 8.)

25 Oct 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $141.82 -1.07
Pfizer Inc. (PFE.N) $36.37 -0.28
Novartis AG (NOVN.S) CHF83.85 0.00
Merck & Co., Inc. (MRK.N) $55.99 -0.93
Roche Holding Ltd. (ROG.S) CHF241.70 0.00
Roche Holding Ltd. (RO.S) CHF242.50 -0.70
Bayer AG (BAYGn.DE) €105.10 -1.30
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.77 -0.89
GlaxoSmithKline plc (GSK.L) 1,290.50 -23.50

Earnings vs. Estimates